Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model
Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of meman...
Saved in:
Published in | Drug metabolism and pharmacokinetics Vol. 30; no. 2; pp. 182 - 187 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.04.2015
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP+ (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells. |
---|---|
AbstractList | Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells.Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells. Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood-brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP(+) (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells. Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to characterize memantine transport at the blood–brain barrier (BBB) using hCMEC/D3 cells, a human BBB model. The initial uptake velocity of memantine in hCMEC/D3 cells was concentration-dependent, and was reduced by metabolic inhibitors, but was independent of extracellular sodium ion and membrane potential. Intracellular alkalization and intracellular acidification markedly reduced and enhanced the uptake, respectively. The uptake was strongly inhibited by quinidine, pyrilamine and verapamil, and was moderately inhibited by TEA (substrate of OCTs and OCTNs) and l-carnitine (substrate of OCTN2), but was not inhibited by MPP+ (substrate of OCTs and PMAT) or ergothioneine (substrate of OCTN1). Although relatively abundant expression of OCTN2 gene has been observed in hCMEC/D3 cells, knockdown of OCTN2 with siRNA did not decrease memantine uptake. Memantine and diphenhydramine each showed inhibition of the other's uptake in a competitive manner. Thus, proton-coupled organic cation antiporter(s) appears to be involved in the transport of memantine in hCMEC/D3 cells, at least in part. Our results indicate that the in vivo BBB permeability of memantine in humans can be predicted from the in vitro uptake clearance in hCMEC/D3 cells. |
Author | Okura, Takashi Higuchi, Kei Deguchi, Yoshiharu Kitamura, Atsushi |
Author_xml | – sequence: 1 givenname: Kei surname: Higuchi fullname: Higuchi, Kei – sequence: 2 givenname: Atsushi surname: Kitamura fullname: Kitamura, Atsushi – sequence: 3 givenname: Takashi surname: Okura fullname: Okura, Takashi – sequence: 4 givenname: Yoshiharu surname: Deguchi fullname: Deguchi, Yoshiharu email: deguchi@pharm.teikyo-u.ac.jp |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/25857234$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kbtu1jAYhi1URA9wAwzIIwNJfUjiRGJBP4UitWKA3fLhC_VPYgfbqdSRO-FauDKc_u3C0MmW_Tw-vO8pOvLBA0KvKakpod35vrbz8rNmhDY1ZTUh3TN0QvueVGRg5KjMeSOqhnfiGJ2mtCeE87ZhL9Axa_tWMN6coN_XMCufnQeco_JpCTFjfYcVXmLIwVcmrMsEFof4Q3lnsFHZBY83Z2MhYufxze76Ynf-kWMD05Teld2y-vfPrcsx4Ju13ID1FIKtdFQF1ypGV8w5WJheouejmhK8ehjP0LdPF993l9XV189fdh-uKtMMJFfcCjDCCE5HPYDQrWKdtWbQYyvallk6Es2YHlrFez1yRhuqmGisYo3mwM_Q28Op5Vu_VkhZzi5tr1Uewpok7QTryNDTtqBvHtBVz2DlEt2s4p18DK0A_QEwMaQUYZTG5ftYSoRukpTIrR-5l1s_cutHUiZLP0Vl_6mPpz8pvT9IUOK5LcHJZBx4A9ZFMFna4J7S_wEye6tr |
CitedBy_id | crossref_primary_10_1039_C6MD00509H crossref_primary_10_1016_j_jep_2020_112581 crossref_primary_10_1016_j_xphs_2018_11_040 crossref_primary_10_3390_pharmaceutics14081683 crossref_primary_10_2217_nnm_2017_0023 crossref_primary_10_1016_j_xphs_2017_04_032 crossref_primary_10_1007_s11095_023_03583_0 crossref_primary_10_1021_acsmedchemlett_8b00099 crossref_primary_10_1111_bcpt_14090 crossref_primary_10_1186_s12987_024_00544_6 crossref_primary_10_1016_j_jconrel_2022_08_051 crossref_primary_10_1021_acs_molpharmaceut_9b00042 crossref_primary_10_1248_bpb_b22_00347 crossref_primary_10_1371_journal_pone_0128890 crossref_primary_10_1016_j_jconrel_2017_03_034 crossref_primary_10_1021_acs_molpharmaceut_6b00818 crossref_primary_10_1002_prp2_879 crossref_primary_10_1177_1179573517693802 crossref_primary_10_4062_biomolther_2019_007 crossref_primary_10_1007_s11095_022_03281_3 crossref_primary_10_1016_j_neuropharm_2017_08_002 crossref_primary_10_1021_acs_molpharmaceut_8b00617 crossref_primary_10_1016_j_bbih_2020_100188 crossref_primary_10_1016_j_pharmthera_2022_108283 crossref_primary_10_3390_futurepharmacol3040046 crossref_primary_10_1016_j_ajps_2015_11_010 crossref_primary_10_1002_jps_24691 crossref_primary_10_1002_bdd_2014 crossref_primary_10_1016_j_expneurol_2022_114181 crossref_primary_10_1016_j_brainres_2021_147581 crossref_primary_10_1124_dmd_120_000115 crossref_primary_10_3390_pharmaceutics12020154 crossref_primary_10_3390_pharmaceutics16030330 crossref_primary_10_1016_j_pnpbp_2021_110409 crossref_primary_10_1248_bpb_b24_00329 crossref_primary_10_1007_s11095_022_03223_z crossref_primary_10_1021_acs_molpharmaceut_0c01104 crossref_primary_10_1016_j_xphs_2020_09_001 crossref_primary_10_3389_fncel_2024_1493644 |
Cites_doi | 10.1016/j.phrs.2004.05.005 10.1007/s11095-012-0926-y 10.1096/fj.04-3458fje 10.1111/j.1471-4159.2011.07208.x 10.1016/j.neuint.2012.11.014 10.1002/jps.24129 10.1111/j.1600-0773.1993.tb01564.x 10.1021/mp900178j 10.1124/dmd.108.022087 10.1186/2045-8118-10-8 10.1016/j.bbamem.2007.08.023 10.1016/0922-4106(91)90113-V 10.1023/A:1018856020583 10.1124/dmd.106.010876 10.1021/mp400316e 10.1038/jcbfm.2009.54 10.1021/mp300570z 10.1254/jphs.12043FP 10.1007/s007020050073 10.2133/dmpk.DMPK-13-RG-058 10.1345/aph.1K619 10.1016/S0028-3908(99)00019-2 10.1002/jps.23535 10.1016/S0969-8051(01)00293-1 10.1002/jps.22567 10.1007/s10334-003-0004-x 10.1371/currents.RRN1291 10.1021/mp3004308 10.1016/j.lfs.2007.01.035 10.1124/mol.54.2.342 10.1002/gps.938 |
ContentType | Journal Article |
Copyright | 2014 The Japanese Society for the Study of Xenobiotics Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2014 The Japanese Society for the Study of Xenobiotics – notice: Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.dmpk.2014.12.006 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1880-0920 |
EndPage | 187 |
ExternalDocumentID | 25857234 10_1016_j_dmpk_2014_12_006 S1347436714000275 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --M 0R~ 29G 2WC 4.4 457 53G 5GY 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABJNI ABMAC ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE AEBSH AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BAWUL BKOJK BKOMP BLXMC CS3 DIK DU5 E3Z EBS EFJIC EFLBG EJD F5P FDB FEDTE FIRID FYGXN GBLVA GX1 HH5 HVGLF HZ~ JMI JSF JSH KOM KQ8 M41 MOJWN M~E O9- OAUVE RJT RNS ROL RZJ SPCBC SSP SSZ T5K TKC TR2 ~G- AAQFI AATTM AAXKI AAYWO AAYXX ACVFH ADCNI AEIPS AEUPX AFJKZ AFPUW AGCQF AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION OVT SSH CGR CUY CVF ECM EFKBS EIF NPM 7X8 |
ID | FETCH-LOGICAL-c490t-3d7ec7c731fb9e7b5a26ddc9bf57552d1f0b22b95a38bf32141a274da24b3e3 |
IEDL.DBID | AIKHN |
ISSN | 1347-4367 1880-0920 |
IngestDate | Mon Jul 21 11:24:54 EDT 2025 Mon Jul 21 06:02:08 EDT 2025 Tue Jul 01 03:08:23 EDT 2025 Thu Apr 24 23:05:22 EDT 2025 Fri Feb 23 02:32:23 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Proton-coupled organic cation antiporter Active transport Memantine hCMEC/D3 cells Blood–brain barrier |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 Copyright © 2014 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c490t-3d7ec7c731fb9e7b5a26ddc9bf57552d1f0b22b95a38bf32141a274da24b3e3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 25857234 |
PQID | 1672609815 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_1672609815 pubmed_primary_25857234 crossref_citationtrail_10_1016_j_dmpk_2014_12_006 crossref_primary_10_1016_j_dmpk_2014_12_006 elsevier_sciencedirect_doi_10_1016_j_dmpk_2014_12_006 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2015-04-01 |
PublicationDateYYYYMMDD | 2015-04-01 |
PublicationDate_xml | – month: 04 year: 2015 text: 2015-04-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Drug metabolism and pharmacokinetics |
PublicationTitleAlternate | Drug Metab Pharmacokinet |
PublicationYear | 2015 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Deo, Theil, Nicolas (bib27) 2013; 10 Hesselink, De Boer, Breimer, Danysz (bib31) 1999; 16 Weksler, Subileau, Perriere, Charneau, Holloway, Leveque (bib12) 2005; 19 Shimomura, Okura, Kato, Couraud, Scherrmann, Terasaki (bib16) 2013; 10 Okura, Kato, Deguchi (bib15) 2014; 29 Kuwayama, Inoue, Kanamori, Tsujikawa, Miyaguchi, Iwata (bib20) 2008; 1778 Beconi, Howland, Park, Lyons, Giuliano, Dominguez (bib4) 2011; 3 Okura, Hattori, Takano, Sato, Hammarlund-Udenaes, Terasaki (bib9) 2008; 36 Uchida, Ohtsuki, Katsukura, Ikeda, Suzuki, Kamiie (bib11) 2011; 117 Lin, Shic, Enriquez, Ross (bib2) 2003; 16 Ohtsuki, Ikeda, Uchida, Sakamoto, Miller, Glacial (bib14) 2013; 7 Mehta, Short, Nicolazzo (bib8) 2013; 10 Parsons, Danysz, Quack (bib29) 1999; 38 Danysz, Parsons (bib3) 2003; 18 Ohta, Inoue, Hayashi, Yuasa (bib18) 2006; 34 Honegger, Quack, Wiesmann (bib19) 1993; 73 Moellentin, Picone, Leadbetter (bib6) 2008; 42 Smith (bib26) 2003; 89 Moritoyo, Hasunuma, Harada, Tateishi, Watanabe, Kotegawa (bib28) 2012; 119 Ametamey, Bruehlmeier, Kneifel, Kokic, Honer, Arigoni (bib7) 2002; 29 Kubo, Shimizu, Kusagawa, Akanuma, Hosoya (bib24) 2013; 102 Kubo, Kusagawa, Tachikawa, Akanuma, Hosoya (bib25) 2013; 30 Kornhuber, Bormann, Hübers, Rusche, Riederer (bib32) 1991; 206 Busch, Karbach, Miska, Gorboulev, Akhoundova, Volk (bib5) 1998; 54 Kitamura, Higuchi, Okura, Deguchi (bib17) 2014; 103 Tega, Akanuma, Kubo, Terasaki, Hosoya (bib22) 2013; 62 Jimenez-Jimenez, Molina, Gomez, Vargas, De Bustos, Benito-Leon (bib1) 1998; 105 André, Debray, Scherrmann, Cisternino (bib21) 2009; 29 Okura, Ito, Ishiguro, Tamai, Deguchi (bib23) 2007; 80 Sadiq, Borgs, Okura, Shimomura, Kato, Deguchi (bib10) 2011; 100 Carl, Lindley, Das, Couraud, Weksler, Romero (bib13) 2010; 2 Sonkusare, Kaul, Ramarao (bib30) 2005; 51 Okura (10.1016/j.dmpk.2014.12.006_bib9) 2008; 36 Okura (10.1016/j.dmpk.2014.12.006_bib15) 2014; 29 Parsons (10.1016/j.dmpk.2014.12.006_bib29) 1999; 38 Carl (10.1016/j.dmpk.2014.12.006_bib13) 2010; 2 Kornhuber (10.1016/j.dmpk.2014.12.006_bib32) 1991; 206 Ametamey (10.1016/j.dmpk.2014.12.006_bib7) 2002; 29 Sonkusare (10.1016/j.dmpk.2014.12.006_bib30) 2005; 51 Mehta (10.1016/j.dmpk.2014.12.006_bib8) 2013; 10 Kitamura (10.1016/j.dmpk.2014.12.006_bib17) 2014; 103 Lin (10.1016/j.dmpk.2014.12.006_bib2) 2003; 16 Sadiq (10.1016/j.dmpk.2014.12.006_bib10) 2011; 100 Ohta (10.1016/j.dmpk.2014.12.006_bib18) 2006; 34 Danysz (10.1016/j.dmpk.2014.12.006_bib3) 2003; 18 Weksler (10.1016/j.dmpk.2014.12.006_bib12) 2005; 19 Shimomura (10.1016/j.dmpk.2014.12.006_bib16) 2013; 10 Kubo (10.1016/j.dmpk.2014.12.006_bib25) 2013; 30 André (10.1016/j.dmpk.2014.12.006_bib21) 2009; 29 Tega (10.1016/j.dmpk.2014.12.006_bib22) 2013; 62 Beconi (10.1016/j.dmpk.2014.12.006_bib4) 2011; 3 Busch (10.1016/j.dmpk.2014.12.006_bib5) 1998; 54 Moritoyo (10.1016/j.dmpk.2014.12.006_bib28) 2012; 119 Uchida (10.1016/j.dmpk.2014.12.006_bib11) 2011; 117 Smith (10.1016/j.dmpk.2014.12.006_bib26) 2003; 89 Honegger (10.1016/j.dmpk.2014.12.006_bib19) 1993; 73 Deo (10.1016/j.dmpk.2014.12.006_bib27) 2013; 10 Kuwayama (10.1016/j.dmpk.2014.12.006_bib20) 2008; 1778 Okura (10.1016/j.dmpk.2014.12.006_bib23) 2007; 80 Moellentin (10.1016/j.dmpk.2014.12.006_bib6) 2008; 42 Ohtsuki (10.1016/j.dmpk.2014.12.006_bib14) 2013; 7 Hesselink (10.1016/j.dmpk.2014.12.006_bib31) 1999; 16 Kubo (10.1016/j.dmpk.2014.12.006_bib24) 2013; 102 Jimenez-Jimenez (10.1016/j.dmpk.2014.12.006_bib1) 1998; 105 |
References_xml | – volume: 29 start-page: 69 year: 2014 end-page: 74 ident: bib15 article-title: Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model publication-title: Drug Metab Pharmacokinet – volume: 42 start-page: 443 year: 2008 end-page: 447 ident: bib6 article-title: Memantine-induced myoclonus and delirium exacerbated by trimethoprim publication-title: Ann Pharmacother – volume: 119 start-page: 324 year: 2012 end-page: 329 ident: bib28 article-title: Effect of renal impairment on the pharmacokinetics of memantine publication-title: J Pharm Sci – volume: 105 start-page: 269 year: 1998 end-page: 277 ident: bib1 article-title: Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease publication-title: J Neural Transm – volume: 10 start-page: 8 year: 2013 ident: bib16 article-title: Functional expression of a proton-coupled organic cation (H publication-title: Fluids Barriers CNS – volume: 1778 start-page: 42 year: 2008 end-page: 50 ident: bib20 article-title: Uptake of 3, 4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells publication-title: Biochim Biophys Acta – volume: 10 start-page: 1581 year: 2013 end-page: 1595 ident: bib27 article-title: Confounding parameters in preclinical assessment of blood–brain barrier permeation: an overview with emphasis on species differences and effect of disease states publication-title: Mol Pharm – volume: 16 start-page: 637 year: 1999 end-page: 642 ident: bib31 article-title: Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study publication-title: Pharm Res – volume: 10 start-page: 4491 year: 2013 end-page: 4498 ident: bib8 article-title: Memantine transport across the mouse blood–brain barrier is mediated by a cationic influx H publication-title: Mol Pharm – volume: 100 start-page: 3912 year: 2011 end-page: 3923 ident: bib10 article-title: Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo publication-title: J Pharm Sci – volume: 34 start-page: 1868 year: 2006 end-page: 1874 ident: bib18 article-title: Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H publication-title: Drug Metab Dispos – volume: 206 start-page: 297 year: 1991 end-page: 300 ident: bib32 article-title: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study publication-title: Eur J Pharmacol – volume: 36 start-page: 2005 year: 2008 end-page: 2013 ident: bib9 article-title: Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone publication-title: Drug Metab Dispos – volume: 80 start-page: 1564 year: 2007 end-page: 1571 ident: bib23 article-title: Blood–brain barrier transport of pramipexole, a dopamine D2 agonist publication-title: Life Sci – volume: 30 start-page: 847 year: 2013 end-page: 856 ident: bib25 article-title: Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier publication-title: Pharm Res – volume: 18 start-page: S23 year: 2003 end-page: S32 ident: bib3 article-title: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence publication-title: Int J Geriatr Psychiatry – volume: 2 start-page: 1057 year: 2010 end-page: 1068 ident: bib13 article-title: ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood–brain barrier cell line, hCMEC/D3 publication-title: Mol Pharm – volume: 73 start-page: 202 year: 1993 end-page: 208 ident: bib19 article-title: Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β – adrenergic transmission publication-title: Pharmacol Toxicol – volume: 38 start-page: 735 year: 1999 end-page: 767 ident: bib29 article-title: Memantine is a clinically well tolerated N-methyl-D-asparate (NMDA) receptor antagonist—a review of preclinical data publication-title: Neuropharmacology – volume: 51 start-page: 1 year: 2005 end-page: 17 ident: bib30 article-title: Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope publication-title: Pharmacol Res – volume: 7 start-page: 289 year: 2013 end-page: 296 ident: bib14 article-title: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood–brain barrier model publication-title: Mol Pharm – volume: 29 start-page: 227 year: 2002 end-page: 231 ident: bib7 article-title: PET studies of publication-title: Nucl Med Biol – volume: 89 start-page: 193 year: 2003 end-page: 208 ident: bib26 article-title: A review of blood-brain barrier transport techniques publication-title: Methods Mol Med – volume: 16 start-page: 29 year: 2003 end-page: 42 ident: bib2 article-title: Reduced glutamate neurotransmission in patients with Alzheimer's disease – an in vivo publication-title: MAGMA – volume: 103 start-page: 3335 year: 2014 end-page: 3341 ident: bib17 article-title: Transport characteristics of tramadol in the blood-brain barrier publication-title: J Pharm Sci – volume: 102 start-page: 3332 year: 2013 end-page: 3342 ident: bib24 article-title: Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter publication-title: J Pharm Sci – volume: 54 start-page: 342 year: 1998 end-page: 352 ident: bib5 article-title: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine publication-title: Mol Pharmacol – volume: 3 start-page: RRN1291 year: 2011 ident: bib4 article-title: Pharmacokinetics of memantine in rats and mice publication-title: PLos Curr – volume: 19 start-page: 1872 year: 2005 end-page: 1874 ident: bib12 article-title: Blood-brain barrier-specific properties of a human adult brain endothelial cell line publication-title: FASEB J – volume: 29 start-page: 1293 year: 2009 end-page: 1304 ident: bib21 article-title: Clonidine transport at the mouse blood–brain barrier by a new H publication-title: J Cereb Blood Flow Metab – volume: 117 start-page: 333 year: 2011 end-page: 345 ident: bib11 article-title: Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors publication-title: J Neurochem – volume: 62 start-page: 173 year: 2013 end-page: 181 ident: bib22 article-title: Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process publication-title: Neurochem Int – volume: 51 start-page: 1 year: 2005 ident: 10.1016/j.dmpk.2014.12.006_bib30 article-title: Dementia of Alzheimer's disease and other neurodegenerative disorders—memantine, a new hope publication-title: Pharmacol Res doi: 10.1016/j.phrs.2004.05.005 – volume: 30 start-page: 847 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib25 article-title: Involvement of a novel organic cation transporter in verapamil transport across the inner blood-retinal barrier publication-title: Pharm Res doi: 10.1007/s11095-012-0926-y – volume: 19 start-page: 1872 year: 2005 ident: 10.1016/j.dmpk.2014.12.006_bib12 article-title: Blood-brain barrier-specific properties of a human adult brain endothelial cell line publication-title: FASEB J doi: 10.1096/fj.04-3458fje – volume: 117 start-page: 333 year: 2011 ident: 10.1016/j.dmpk.2014.12.006_bib11 article-title: Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors publication-title: J Neurochem doi: 10.1111/j.1471-4159.2011.07208.x – volume: 62 start-page: 173 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib22 article-title: Blood-to-brain influx transport of nicotine at the rat blood–brain barrier: involvement of a pyrilamine-sensitive organic cation transport process publication-title: Neurochem Int doi: 10.1016/j.neuint.2012.11.014 – volume: 103 start-page: 3335 year: 2014 ident: 10.1016/j.dmpk.2014.12.006_bib17 article-title: Transport characteristics of tramadol in the blood-brain barrier publication-title: J Pharm Sci doi: 10.1002/jps.24129 – volume: 73 start-page: 202 year: 1993 ident: 10.1016/j.dmpk.2014.12.006_bib19 article-title: Evidence for lysosomotropism of memantine in cultured human cells: cellular kinetics and effects of memantine on phospholipid content and composition, membrane fluidity and β – adrenergic transmission publication-title: Pharmacol Toxicol doi: 10.1111/j.1600-0773.1993.tb01564.x – volume: 2 start-page: 1057 year: 2010 ident: 10.1016/j.dmpk.2014.12.006_bib13 article-title: ABC and SLC transporter expression and proton oligopeptide transporter (POT) mediated permeation across the human blood–brain barrier cell line, hCMEC/D3 publication-title: Mol Pharm doi: 10.1021/mp900178j – volume: 36 start-page: 2005 year: 2008 ident: 10.1016/j.dmpk.2014.12.006_bib9 article-title: Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone publication-title: Drug Metab Dispos doi: 10.1124/dmd.108.022087 – volume: 10 start-page: 8 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib16 article-title: Functional expression of a proton-coupled organic cation (H+/OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood–brain barrier model publication-title: Fluids Barriers CNS doi: 10.1186/2045-8118-10-8 – volume: 1778 start-page: 42 year: 2008 ident: 10.1016/j.dmpk.2014.12.006_bib20 article-title: Uptake of 3, 4-methylenedioxymethamphetamine and its related compounds by a proton-coupled transport system in Caco-2 cells publication-title: Biochim Biophys Acta doi: 10.1016/j.bbamem.2007.08.023 – volume: 206 start-page: 297 year: 1991 ident: 10.1016/j.dmpk.2014.12.006_bib32 article-title: Effects of the 1-amino-adamantanes at the MK-801-binding site of the NMDA-receptor-gated ion channel: a human postmortem brain study publication-title: Eur J Pharmacol doi: 10.1016/0922-4106(91)90113-V – volume: 16 start-page: 637 year: 1999 ident: 10.1016/j.dmpk.2014.12.006_bib31 article-title: Brain penetration and in vivo recovery of NMDA receptor antagonists amantadine and memantine: a quantitative microdialysis study publication-title: Pharm Res doi: 10.1023/A:1018856020583 – volume: 34 start-page: 1868 year: 2006 ident: 10.1016/j.dmpk.2014.12.006_bib18 article-title: Molecular identification and functional characterization of rat multidrug and toxin extrusion type transporter 1 as an organic cation/H+ antiporter in the kidney publication-title: Drug Metab Dispos doi: 10.1124/dmd.106.010876 – volume: 10 start-page: 4491 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib8 article-title: Memantine transport across the mouse blood–brain barrier is mediated by a cationic influx H+ antiporter publication-title: Mol Pharm doi: 10.1021/mp400316e – volume: 29 start-page: 1293 year: 2009 ident: 10.1016/j.dmpk.2014.12.006_bib21 article-title: Clonidine transport at the mouse blood–brain barrier by a new H+ antiporter that interacts with addictive drugs publication-title: J Cereb Blood Flow Metab doi: 10.1038/jcbfm.2009.54 – volume: 10 start-page: 1581 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib27 article-title: Confounding parameters in preclinical assessment of blood–brain barrier permeation: an overview with emphasis on species differences and effect of disease states publication-title: Mol Pharm doi: 10.1021/mp300570z – volume: 119 start-page: 324 year: 2012 ident: 10.1016/j.dmpk.2014.12.006_bib28 article-title: Effect of renal impairment on the pharmacokinetics of memantine publication-title: J Pharm Sci doi: 10.1254/jphs.12043FP – volume: 105 start-page: 269 year: 1998 ident: 10.1016/j.dmpk.2014.12.006_bib1 article-title: Neurotransmitter amino acids in cerebrospinal fluid of patients with Alzheimer's disease publication-title: J Neural Transm doi: 10.1007/s007020050073 – volume: 29 start-page: 69 year: 2014 ident: 10.1016/j.dmpk.2014.12.006_bib15 article-title: Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model publication-title: Drug Metab Pharmacokinet doi: 10.2133/dmpk.DMPK-13-RG-058 – volume: 42 start-page: 443 year: 2008 ident: 10.1016/j.dmpk.2014.12.006_bib6 article-title: Memantine-induced myoclonus and delirium exacerbated by trimethoprim publication-title: Ann Pharmacother doi: 10.1345/aph.1K619 – volume: 38 start-page: 735 year: 1999 ident: 10.1016/j.dmpk.2014.12.006_bib29 article-title: Memantine is a clinically well tolerated N-methyl-D-asparate (NMDA) receptor antagonist—a review of preclinical data publication-title: Neuropharmacology doi: 10.1016/S0028-3908(99)00019-2 – volume: 102 start-page: 3332 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib24 article-title: Propranolol transport across the inner blood-retinal barrier: potential involvement of a novel organic cation transporter publication-title: J Pharm Sci doi: 10.1002/jps.23535 – volume: 29 start-page: 227 year: 2002 ident: 10.1016/j.dmpk.2014.12.006_bib7 article-title: PET studies of 18F-memantine in healthy volunteers publication-title: Nucl Med Biol doi: 10.1016/S0969-8051(01)00293-1 – volume: 100 start-page: 3912 year: 2011 ident: 10.1016/j.dmpk.2014.12.006_bib10 article-title: Diphenhydramine active uptake at the blood–brain barrier and its interaction with oxycodone in vitro and in vivo publication-title: J Pharm Sci doi: 10.1002/jps.22567 – volume: 16 start-page: 29 year: 2003 ident: 10.1016/j.dmpk.2014.12.006_bib2 article-title: Reduced glutamate neurotransmission in patients with Alzheimer's disease – an in vivo 13C magnetic resonance spectroscopy study publication-title: MAGMA doi: 10.1007/s10334-003-0004-x – volume: 3 start-page: RRN1291 year: 2011 ident: 10.1016/j.dmpk.2014.12.006_bib4 article-title: Pharmacokinetics of memantine in rats and mice publication-title: PLos Curr doi: 10.1371/currents.RRN1291 – volume: 89 start-page: 193 year: 2003 ident: 10.1016/j.dmpk.2014.12.006_bib26 article-title: A review of blood-brain barrier transport techniques publication-title: Methods Mol Med – volume: 7 start-page: 289 year: 2013 ident: 10.1016/j.dmpk.2014.12.006_bib14 article-title: Quantitative targeted absolute proteomic analysis of transporters, receptors and junction proteins for validation of human cerebral microvascular endothelial cell line hCMEC/D3 as a human blood–brain barrier model publication-title: Mol Pharm doi: 10.1021/mp3004308 – volume: 80 start-page: 1564 year: 2007 ident: 10.1016/j.dmpk.2014.12.006_bib23 article-title: Blood–brain barrier transport of pramipexole, a dopamine D2 agonist publication-title: Life Sci doi: 10.1016/j.lfs.2007.01.035 – volume: 54 start-page: 342 year: 1998 ident: 10.1016/j.dmpk.2014.12.006_bib5 article-title: Human neurons express the polyspecific cation transporter hOCT2, which translocates monoamine neurotransmitters, amantadine, and memantine publication-title: Mol Pharmacol doi: 10.1124/mol.54.2.342 – volume: 18 start-page: S23 year: 2003 ident: 10.1016/j.dmpk.2014.12.006_bib3 article-title: The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence publication-title: Int J Geriatr Psychiatry doi: 10.1002/gps.938 |
SSID | ssj0033542 |
Score | 2.2405312 |
Snippet | Memantine is clinically used for the treatment of patients with Alzheimer's disease and is highly distributed to the brain. The aim of this study is to... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 182 |
SubjectTerms | Active transport Biological Transport Blood-Brain Barrier - cytology Blood-Brain Barrier - drug effects Blood-Brain Barrier - metabolism Blood–brain barrier Cell Line, Transformed Endothelial Cells - drug effects Endothelial Cells - metabolism Feasibility Studies hCMEC/D3 cells Humans Kinetics Memantine Memantine - metabolism Membrane Transport Modulators - pharmacology Models, Biological Organic Cation Transport Proteins - antagonists & inhibitors Organic Cation Transport Proteins - metabolism Proton-coupled organic cation antiporter RNA Interference Transfection |
Title | Memantine transport by a proton-coupled organic cation antiporter in hCMEC/D3 cells, an in vitro human blood-brain barrier model |
URI | https://dx.doi.org/10.1016/j.dmpk.2014.12.006 https://www.ncbi.nlm.nih.gov/pubmed/25857234 https://www.proquest.com/docview/1672609815 |
Volume | 30 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELba7YUL4s1SqAYJ9UKjTew43hyrpWUBbVWpRdqb5ae60CarbbbSHvkn_BZ-GZ44aYUEPXCMlZEtjz0Pa-b7CHmnHBXOMZWkPlchQVHhShXMJVQZ71PjlOfYKDw7KaZf889zPt8ik74XBssqO9sfbXprrbuRUbebo-ViMTrDJsicFYg4h8kV3yY7NHjXdEB2Dj99mZ70Bpkx3nLo4P8JCnS9M7HMy14tv2OFV96-CiLx0d_907_iz9YPHT8iD7sAEg7jGh-TLVc9IfunEYF6cwDndw1V1wewD6d32NSbp-THzF0pJIdw0PSw5qA3oAABG-oqMfV6eeksRLYnA_FFD1CmhUBfwaKCi8nsaDL6wACf_cMsqgqjv37eLJpVDS3rH8SCeI0EFKDVCnnxoGXdeUbOjo_OJ9OkY2FITF6mTcKscEYYwTKvSyc0V7Sw1pTah0iPU5v5VFOqS67YWHvkPcpUSHWtorlmjj0ng6qu3EsC1pcpT40IAarA97wxK3JfGMNsIZjRdEiyfuel6QDKkSfjUvaVaN8kakuitmRGZdDWkLy_lVlGeI57_-a9QuUfh0wG_3Gv3Nte-zLcPtxbVbl6fS2zQoSEsBxnfEhexGNxuw4aMjFBWf7qP2fdJQ_CF49lQq_JoFmt3ZsQATV6rzvhe2T74zz7DfaFB28 |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwELZKe4AL4s3yHCTUC402seN4c6yWVlvaXVXqIvVm-SkW2mS1zSLtkX_Cb-GX4YmTVkjQA1cnI1ue8XjGmvk-Qt4rR4VzTCWpz1VIUFQ4UgVzCVXG-9Q45Tk2Ck9nxeRz_umcn2-Rcd8Lg2WVne-PPr311t3IsNvN4XKxGJ5hE2TOCkScw-SK3yE7iE4VzHxn_-h4MusdMmO85dDB_xMU6HpnYpmXvVx-wwqvvH0VROKjv99P_4o_23vo8AG53wWQsB_X-JBsueoR2T2NCNSbPZjfNFRd7cEunN5gU28ekx9Td6mQHMJB08Oag96AAgRsqKvE1OvlhbMQ2Z4MxBc9QJkWAn0Fiwq-jKcH4-FHBvjsH2ZRVRj99fP7olnV0LL-QSyI10hAAVqtkBcPWtadJ-Ts8GA-niQdC0Ni8jJtEmaFM8IIlnldOqG5ooW1ptQ-RHqc2synmlJdcsVG2iPvUaZCqmsVzTVz7CnZrurKPSdgfZny1IgQoAp8zxuxIveFMcwWghlNByTrd16aDqAceTIuZF-J9lWitiRqS2ZUBm0NyIdrmWWE57j1b94rVP5hZDLcH7fKveu1L8Ppw71VlavXVzIrREgIy1HGB-RZNIvrddCQiQnK8hf_Oetbcncyn57Ik6PZ8UtyL3zhsWToFdluVmv3OkRDjX7TWftvSecJbQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Memantine+transport+by+a+proton-coupled+organic+cation+antiporter+in+hCMEC%2FD3+cells%2C+an+in%C2%A0vitro+human+blood-brain+barrier+model&rft.jtitle=Drug+metabolism+and+pharmacokinetics&rft.au=Higuchi%2C+Kei&rft.au=Kitamura%2C+Atsushi&rft.au=Okura%2C+Takashi&rft.au=Deguchi%2C+Yoshiharu&rft.date=2015-04-01&rft.issn=1347-4367&rft.volume=30&rft.issue=2&rft.spage=182&rft.epage=187&rft_id=info:doi/10.1016%2Fj.dmpk.2014.12.006&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_dmpk_2014_12_006 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-4367&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-4367&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-4367&client=summon |